Abstract: Provided are an antigen-binding polypeptide binding to CD47 or an antigen-binding portion thereof, nucleic acids encoding the polypeptide, vector, cell or pharmaceutical composition. The polypeptide can reduce a tumor or inhibit the growth of tumor cells, treat cancer, promote macrophage phagocytosis, and the like.

Abstract: Provided are a phase quadrature four-wavelength demodulation system and method of an optical fiber F-P cavity sensor. The phase quadrature four-wavelength demodulation system of the optical fiber F-P cavity sensor includes a flat ASE broadband light source, an optical fiber circulator, a dense wavelength division multiplexer, a photoelectric detector, and a data acquisition processing unit. The flat ASE broadband light source is connected to the optical fiber circulator, the optical fiber circulator is connected to the dense wavelength division multiplexer, the dense wavelength division multiplexer is connected to the photoelectric detector, and the photoelectric detector is connected to the data acquisition processing unit.

Abstract: Provided are a phase quadrature four-wavelength demodulation system and method of an optical fiber F-P cavity sensor. The phase quadrature four-wavelength demodulation system of the optical fiber F-P cavity sensor includes a flat ASE broadband light source, an optical fiber circulator, a dense wavelength division multiplexer, a photoelectric detector, and a data acquisition processing unit. The flat ASE broadband light source is connected to the optical fiber circulator, the optical fiber circulator is connected to the dense wavelength division multiplexer, the dense wavelength division multiplexer is connected to the photoelectric detector, and the photoelectric detector is connected to the data acquisition processing unit.

Abstract: Provided herein are methods of killing or reducing the number of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, decreasing the accumulation of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, that include administering to the subject a therapeutically effective amount of one or more common gamma-chain family cytokine receptor activating agent(s) and/or one or more agent(s) that result(s) in a decrease in the activation of a TGF-? receptor.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: Identifying a likely cause of a problem in an application can include: injecting a series of a set of predetermined faults into the application; sampling a subset of a set of training features from the application during each predetermined fault injected into the application and labeling each subset with an identifier of the corresponding predetermined fault; and training a classifier to identify the likely cause by associating a set of real-time features sampled from the application that pertain to the problem to one or more of the predetermined faults in response to the training features.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: Provided herein are proteins comprising an anti-CD26 antigen-binding domain. Also provided herein are methods of treating an aging-related disease or an inflammatory disease in a subject that include administering to the subject one of these proteins or a cell expressing one of these proteins.

Abstract: Provided herein are multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: A system and method for performing an operational metric analysis for a virtual appliance uses application operational data from multiple instances of the virtual appliance. The application operational data is then used to generate an operational metric prediction for the virtual appliance.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: Provided herein are methods of killing or reducing the number of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, decreasing the accumulation of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, that include administering to the subject a therapeutically effective amount of one or more common gamma-chain family cytokine receptor activating agent(s) and/or one or more agent(s) that result(s) in a decrease in the activation of a TGF-? receptor.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: Identifying a likely cause of a problem in an application can include: injecting a series of a set of predetermined faults into the application; sampling a subset of a set of training features from the application during each predetermined fault injected into the application and labeling each subset with an identifier of the corresponding predetermined fault; and training a classifier to identify the likely cause by associating a set of real-time features sampled from the application that pertain to the problem to one or more of the predetermined faults in response to the training features.

Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant, a cytokine receptor or cytokine ligand, and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).